Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | UBE2M | P61081 | 1/20 | 0.54 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796219 | 0.93 | UBE2M (0.54) | SIGMAR1KMT2AMEN1LMNAUBE2M | |
| SCHEMBL4125301 | 0.80 | ACHE (0.57) | SIGMAR1KMT2AMEN1MCHR1POLB | |
| SCHEMBL1306000 | 0.80 | OPRM1 (0.61) | SIGMAR1 | |
| SCHEMBL5672524 | 0.79 | SIGMAR1 (0.50) | SIGMAR1LMNAUBE2MDCUN1D1KDM4E | |
| SCHEMBL1921490 | 0.77 | SIGMAR1 (0.56) | SIGMAR1KMT2AMEN1UBE2MDCUN1D1 | |
| SCHEMBL10893210 | 0.77 | CHRM2 (0.56) | SIGMAR1KMT2AMEN1 | |
| SCHEMBL1062230 | 0.75 | OPRM1 (0.56) | SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL4125164 | 0.75 | SIGMAR1 (0.77) | SIGMAR1KMT2AMEN1MCHR1SMN1; SMN2 | |
| SCHEMBL16472966 | 0.75 | TSHR (0.62) | SIGMAR1KMT2AMEN1MCHR1TSHR | |
| Trifluoroacetic Acid SCHEMBL1920549 | 0.75 | SIGMAR1 (0.57) | SIGMAR1KMT2AMEN1LMNAMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | SIGMAR1 334/4885KMT2A 1253/4885MEN1 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.